Ascendia Patented IP Technologies Featured in Annual Report

Ascendia Pharmaceuticals’ suite of three patented IP technologies – AmorSol, EmulSol, and NanoSol – is included in an annual special report on the state of bioavailability and solubility. The report was published in Drug Development & Delivery, the leading trade media property.

Jim Huang, PhD, CEO, of Ascendia Pharmaceuticals, explains how these advanced approaches allow Ascendia meet stringent timelines and solve difficult challenges with compounds in the article. The company’s approach to utilize lipid nanoparticles (LNP) in its technologies to improve biosolubility and achieve more effective sustained-release properties is also outlined.